{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T19:13:44Z","timestamp":1773256424427,"version":"3.50.1"},"reference-count":68,"publisher":"MDPI AG","issue":"22","license":[{"start":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T00:00:00Z","timestamp":1762473600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diagnostics"],"abstract":"<jats:p>Background: Fluoroquinolone (FQ) resistance in Escherichia coli (E. coli) undermines empiric therapy and often coincides with multidrug resistance (MDR). Because sequencing is not routinely available in many laboratories, we evaluated a phenotype-first, sequencing-independent diagnostic framework deployable on standard platforms. Methods: We profiled 45 archived E. coli isolates for susceptibility (Clinical and Laboratory Standards Institute [CLSI]-guided), extended-spectrum \u03b2-lactamase (ESBL) and AmpC \u03b2-lactamase (AmpC) phenotypes, MDR, and multiple-antibiotic resistance (MAR) indices. Ten founders (five FQ-susceptible [FQ-S], five low-level resistant [LLR]) seeded 20 parallel lineages exposed to stepwise ciprofloxacin. We tracked minimum inhibitory concentrations (MICs), collateral resistance, growth kinetics, and biofilm biomass using matrix-assisted laser desorption\/ionization time-of-flight mass spectrometry (MALDI-TOF MS) for identification, automated and reference antimicrobial susceptibility testing (AST), growth-curve analysis, and crystal violet microtiter assays. The intended use is a sequencing-independent workflow for routine laboratories\u2014especially where whole-genome sequencing is not readily available\u2014working with archived or prospective clinical E. coli. This workflow is best applied when local FQ nonsusceptibility threatens empiric reliability; inputs include standard ID\/AST with simple growth and biofilm assays. Primary outputs include: (i) MIC trajectories with time to high-level resistance (HLR), (ii) \u0394MAR-summarized collateral resistance with class-level susceptible-to-resistant conversions, and (iii) concise fitness\/biofilm summaries to guide empiric-policy refresh and early de-escalation. Results: At baseline, ciprofloxacin nonsusceptibility was 40.0%; ESBL and AmpC phenotypes were confirmed in 28.9% and 15.6%, respectively; 46.7% met the MDR definition; and the median MAR index was 0.29. During evolution, 70% of lineages reached HLR (MIC \u2265 4 \u03bcg\/mL), with earlier conversion from LLR versus FQ-S founders (median 7 vs. 11 passages). Collateral resistance emerged most often to third-generation cephalosporins (3GCs), trimethoprim\u2013sulfamethoxazole, and tetracyclines, while carbapenem activity was preserved. MAR increased in parallel with rising MICs. Resistance acquisition imposed modest fitness costs (slightly reduced growth rates and longer lag phases) that were partly offset under subinhibitory ciprofloxacin, whereas biofilm biomass changed little. Conclusions: this phenotype-first, routine-laboratory workflow rapidly maps FQ resistance and clinically relevant co-selection in E. coli. In high-resistance settings, empiric FQ use is difficult to justify, and MAR trends provide practical co-selection signals for stewardship. This reproducible framework complements genomic surveillance and is directly applicable where sequencing is unavailable.<\/jats:p>","DOI":"10.3390\/diagnostics15222831","type":"journal-article","created":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T10:35:31Z","timestamp":1762770931000},"page":"2831","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Phenotype-First Diagnostic Framework for Tracking Fluoroquinolone Resistance in Escherichia coli"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1699-6263","authenticated-orcid":false,"given":"Eman","family":"Marzouk","sequence":"first","affiliation":[{"name":"Department of Public Health, College of Applied Medical Sciences, Qassim University, P.O. Box 6666, Buraydah 51452, Saudi Arabia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9997-7476","authenticated-orcid":false,"given":"Abdulaziz M.","family":"Almuzaini","sequence":"additional","affiliation":[{"name":"Department of Veterinary Preventive Medicine, College of Veterinary Medicine, Qassim University, Buraydah 51452, Saudi Arabia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,11,7]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Tamma, P.D., Heil, E.L., Justo, J.A., Mathers, A.J., Satlin, M.J., and Bonomo, R.A. (2024). Infectious Diseases Society of America 2024 guidance on the treatment of antimicrobial-resistant gram-negative infections. Clin. Infect. Dis., ciae403.","DOI":"10.1093\/cid\/ciae403"},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Ajulo, S., and Awosile, B. (2024). Global antimicrobial resistance and use surveillance system (GLASS 2022): Investigating the relationship between antimicrobial resistance and antimicrobial consumption data across the participating countries. PLoS ONE, 19.","DOI":"10.1371\/journal.pone.0297921"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1093\/jac\/dkq471","article-title":"Significant ecological impact on the progression of fluoroquinolone resistance in Escherichia coli with increased community use of moxifloxacin, levofloxacin and amoxicillin\/clavulanic acid","volume":"66","author":"Cuevas","year":"2011","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_4","unstructured":"WHO (2024). WHO Bacterial Priority Pathogens List, 2024: Bacterial Pathogens of Public Health Importance to Guide Research, Development and Strategies to Prevent and Control Antimicrobial Resistance, World Health Organization. Available online: https:\/\/www.who.int\/publications\/i\/item\/9789240093461."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"e00862-20","DOI":"10.1128\/AAC.00862-20","article-title":"Escherichia coli resistance to fluoroquinolones in community-acquired uncomplicated urinary tract infection in women: A systematic review","volume":"64","author":"Stapleton","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_6","unstructured":"WHO (2022). Global Antimicrobial Resistance and Use Surveillance System (GLASS) Report: 2022, World Health Organization. Available online: https:\/\/www.who.int\/pubLications\/i\/item\/9789240062702."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Ruiz-Lievano, A.P., Cervantes-Flores, F., Nava-Torres, A., Carbajal-Morales, P.J., Villase\u00f1or-Garcia, L.F., and Zavala-Cerna, M.G. (2024). Fluoroquinolone resistance in Escherichia coli causing community-acquired urinary tract infections: A systematic review. Microorganisms, 12.","DOI":"10.20944\/preprints202407.2008.v1"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/nyas.12830","article-title":"Mechanisms of drug resistance: Quinolone resistance","volume":"1354","author":"Hooper","year":"2015","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1128\/CMR.00016-09","article-title":"Plasmid-mediated quinolone resistance: A multifaceted threat","volume":"22","author":"Strahilevitz","year":"2009","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1038\/nrmicro2319","article-title":"Antibiotic resistance and its cost: Is it possible to reverse resistance?","volume":"8","author":"Andersson","year":"2010","journal-title":"Nat. Rev. Microbiol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"5806","DOI":"10.1128\/AAC.00281-21","article-title":"The AcrAB-TolC efflux pump impacts persistence and resistance development in stationary-phase Escherichia coli following delafloxacin treatment","volume":"65","author":"Byrd","year":"2021","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Nesse, L.L., Osland, A.M., Asal, B., and Mo, S.S. (2023). Evolution of antimicrobial resistance in E. coli biofilm treated with high doses of ciprofloxacin. Front. Microbiol., 14.","DOI":"10.3389\/fmicb.2023.1246895"},{"key":"ref_13","first-page":"1","article-title":"Quantitative and qualitative assessment methods for biofilm growth: A mini-review","volume":"6","author":"Wilson","year":"2017","journal-title":"Res. Rev. J. Eng. Technol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"e00511-22","DOI":"10.1128\/aac.00511-22","article-title":"Escherichia coli ST1193: Following in the footsteps of E. coli ST131","volume":"66","author":"Pitout","year":"2022","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_15","first-page":"e000295","article-title":"Clonal ST131-H 22 Escherichia coli strains from a healthy pig and a human urinary tract infection carry highly similar resistance and virulence plasmids","volume":"5","author":"Reid","year":"2019","journal-title":"Microb. Genom."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"e1056","DOI":"10.1016\/S2666-5247(23)00284-7","article-title":"Exploiting genomics for antimicrobial resistance surveillance at One Health interfaces","volume":"4","author":"Muloi","year":"2023","journal-title":"Lancet Microbe"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"e01479-24","DOI":"10.1128\/aac.01479-24","article-title":"Pathogen genomics in healthcare: Overcoming barriers to proactive surveillance","volume":"69","author":"Sundermann","year":"2025","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Teichmann, L., Luitwieler, S., Bengtsson-Palme, J., and Ter Kuile, B. (2025). Fluoroquinolone-specific resistance trajectories in E. coli and their dependence on the SOS-response. BMC Microbiol., 25.","DOI":"10.1186\/s12866-025-03771-5"},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Dash, J., Naykodi, A., Mohakud, N.K., and Deb, S. (2024). MALDI TOF-MS for microbial identification and diagnosis. Evolving Landscape of Molecular Diagnostics, Elsevier.","DOI":"10.1016\/B978-0-323-99316-6.00006-8"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1373\/clinchem.2014.221770","article-title":"MALDI-TOF MS for the diagnosis of infectious diseases","volume":"61","author":"Patel","year":"2015","journal-title":"Clin. Chem."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Elbehiry, A., and Abalkhail, A. (2025). Spectral Precision: Recent Advances in Matrix-Assisted Laser Desorption\/Ionization Time-of-Flight Mass Spectrometry for Pathogen Detection and Resistance Profiling. Microorganisms, 13.","DOI":"10.3390\/microorganisms13071473"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1016\/j.sjbs.2021.01.018","article-title":"Multidrug-resistant Escherichia coli in Raw Milk: Molecular Characterization and the potential impact of camel\u2019s Urine as an Antibacterial Agent","volume":"28","author":"Elbehiry","year":"2021","journal-title":"Saudi J. Biol. Sci."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Papadomanolaki, A., Siopi, M., Karakosta, P., Vourli, S., and Pournaras, S. (2022). Comparative Evaluation of Vitek 2 and Etest versus Broth microdilution for ceftazidime\/avibactam and ceftolozane\/tazobactam susceptibility testing of Enterobacterales and Pseudomonas aeruginosa. Antibiotics, 11.","DOI":"10.3390\/antibiotics11070865"},{"key":"ref_24","first-page":"210","article-title":"M100 performance standards for antimicrobial susceptibility testing","volume":"27","author":"Weinstein","year":"2018","journal-title":"Clin. Lab. Stand. Inst."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1038\/nprot.2007.521","article-title":"Agar and broth dilution methods to determine the minimal inhibitory concentration (MIC) of antimicrobial substances","volume":"3","author":"Wiegand","year":"2008","journal-title":"Nat. Protoc."},{"key":"ref_26","first-page":"e2437","article-title":"Microtiter Dish Biofilm Formation Assay","volume":"47","year":"2011","journal-title":"J. Vis. Exp."},{"key":"ref_27","unstructured":"ASM (2025, September 24). MacConkey Agar Plates\u2014Protocols. Available online: https:\/\/asm.org\/protocols\/macconkey-agar-plates-protocols."},{"key":"ref_28","unstructured":"CLSI (2025). Performance Standards for Antimicrobial Susceptibility Testing (M100), Clinical and Laboratory Standards Institute. Available online: https:\/\/clsi.org\/shop\/standards\/m100\/?."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"e00166-25","DOI":"10.1128\/spectrum.00166-25","article-title":"Evaluation of the VITEK 2 AST-N439 card for susceptibility testing of novel \u03b2-lactam\/\u03b2-lactamase inhibitor combinations and colistin in carbapenem-non-susceptible gram-negative bacilli","volume":"13","author":"Kim","year":"2025","journal-title":"Microbiol. Spectr."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"4163","DOI":"10.1128\/JCM.43.8.4163-4167.2005","article-title":"Inhibitor-based methods for detection of plasmid-mediated AmpC \u03b2-lactamases in Klebsiella spp., Escherichia coli, and Proteus mirabilis","volume":"43","author":"Coudron","year":"2005","journal-title":"J. Clin. Microbiol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1111\/j.1469-0691.2011.03570.x","article-title":"Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: An international expert proposal for interim standard definitions for acquired resistance","volume":"18","author":"Magiorakos","year":"2012","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1128\/aem.46.1.165-170.1983","article-title":"Multiple antibiotic resistance indexing of Escherichia coli to identify high-risk sources of fecal contamination of foods","volume":"46","author":"Krumperman","year":"1983","journal-title":"Appl. Environ. Microbiol."},{"key":"ref_33","unstructured":"WHO (2025, September 29). Antimicrobial Resistance. Available online: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/antimicrobial-resistance."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1016\/S0140-6736(24)01867-1","article-title":"Global burden of bacterial antimicrobial resistance 1990\u20132021: A systematic analysis with forecasts to 2050","volume":"404","author":"Naghavi","year":"2024","journal-title":"Lancet"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/S1473-3099(25)00118-5","article-title":"The WHO Bacterial Priority Pathogens List 2024: A prioritisation study to guide research, development, and public health strategies against antimicrobial resistance","volume":"25","author":"Sati","year":"2025","journal-title":"Lancet Infect. Dis."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Calderaro, A., and Chezzi, C. (2024). MALDI-TOF MS: A reliable tool in the real life of the clinical microbiology laboratory. Microorganisms, 12.","DOI":"10.3390\/microorganisms12020322"},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Elbehiry, A., Aldubaib, M., Abalkhail, A., Marzouk, E., Albeloushi, A., Moussa, I., Ibrahem, M., Albazie, H., Alqarni, A., and Anagreyyah, S. (2022). How MALDI-TOF mass spectrometry technology contributes to microbial infection control in healthcare settings. Vaccines, 10.","DOI":"10.3390\/vaccines10111881"},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Anorue, M., Ejikeugwu, C., Iroha, C.S., David, E.E., Nwabueze, E.F., and Iroha, I.R. (2025). Extended spectrum beta-lactamase producing Escherichia coli encoding aminoglycoside and fluoroquinolone resistant genes in urinary tract infection patients in a tertiary hospital in Nigeria. BMC Infect. Dis., 25.","DOI":"10.1186\/s12879-025-11561-7"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"102","DOI":"10.3947\/ic.2024.0108","article-title":"Genetic Determinants of Carbapenem and Fluoroquinolone Resistance in Escherichia coli Isolates of Clinical Origin","volume":"57","author":"Lawal","year":"2025","journal-title":"Infect. Chemother."},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Topa, A.-E., Ionescu, C., Pinzaru, A., Mocanu, E., Iancu, A.M., Dumea, E., Nitu, B.F., Panculescu, F.G., and Cambrea, S.C. (2025). Challenges in the Treatment of Urinary Tract Infections: Antibiotic Resistance Profiles of Escherichia coli Strains Isolated from Young and Elderly Patients in a Southeastern Romanian Hospital. Biomedicines, 13.","DOI":"10.3390\/biomedicines13051066"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1111\/j.1469-0691.2004.01057.x","article-title":"Antibiotic resistance of Escherichia coli from community-acquired urinary tract infections in relation to demographic and clinical data","volume":"11","author":"Serrano","year":"2005","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Garc\u00eda-Meni\u00f1o, I., Garc\u00eda, V., Lumbreras-Iglesias, P., Fern\u00e1ndez, J., and Mora, A. (2024). Fluoroquinolone resistance in complicated urinary tract infections: Association with the increased occurrence and diversity of Escherichia coli of clonal complex 131, together with ST1193. Front. Cell. Infect. Microbiol., 14.","DOI":"10.3389\/fcimb.2024.1351618"},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Zlamal, J.E., Leyn, S.A., Iyer, M., Elane, M.L., Wong, N.A., Wamsley, J.W., Vercruysse, M., Garcia-Alcalde, F., and Osterman, A.L. (2021). Shared and unique evolutionary trajectories to ciprofloxacin resistance in gram-negative bacterial pathogens. mBio, 12.","DOI":"10.1128\/mBio.00987-21"},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"de Lastours, V., El Meouche, I., Chau, F., Beghain, J., Chevret, D., Aubert-Frambourg, A., Clermont, O., Royer, G., Bouvet, O., and Denamur, E. (2022). Evolution of fluoroquinolone-resistant Escherichia coli in the gut after ciprofloxacin treatment. Int. J. Med. Microbiol., 312.","DOI":"10.1016\/j.ijmm.2022.151548"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1093\/molbev\/msaa032","article-title":"Population bottlenecks strongly influence the evolutionary trajectory to fluoroquinolone resistance in Escherichia coli","volume":"37","author":"Garoff","year":"2020","journal-title":"Mol. Biol. Evol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/ng.1034","article-title":"Evolutionary paths to strong antibiotic resistance under dynamically sustained drug stress","volume":"44","author":"Toprak","year":"2011","journal-title":"Nat. Genet."},{"key":"ref_47","first-page":"1029","article-title":"Mutation supply and relative fitness shape the genotypes of ciprofloxacin-resistant Escherichia coli","volume":"34","author":"Huseby","year":"2017","journal-title":"Mol. Biol. Evol."},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Jacoby, G.A., Strahilevitz, J., and Hooper, D.C. (2015). Plasmid-Mediated Quinolone Resistance. Plasmids: Biology and Impact in Biotechnology and Discovery, Wiley.","DOI":"10.1128\/9781555818982.ch25"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.2217\/fmb.14.66","article-title":"Multidrug efflux pumps in Gram-negative bacteria and their role in antibiotic resistance","volume":"9","author":"Blair","year":"2014","journal-title":"Future Microbiol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1093\/jac\/dkg050","article-title":"The importance of efflux pumps in bacterial antibiotic resistance","volume":"51","author":"Webber","year":"2003","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Chetri, S. (2023). The culmination of multidrug-resistant efflux pumps vs. meager antibiotic arsenal era: Urgent need for an improved new generation of EPIs. Front. Microbiol., 14.","DOI":"10.3389\/fmicb.2023.1149418"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1111\/eva.12196","article-title":"The fitness costs of antibiotic resistance mutations","volume":"8","author":"Melnyk","year":"2015","journal-title":"Evol. Appl."},{"key":"ref_53","unstructured":"IDSA (2025, September 29). IDSA 2024 Guidance on the Treatment of Antimicrobial Resistant Gram-Negative Infections. Available online: https:\/\/www.idsociety.org\/practice-guideline\/amr-guidance\/."},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"L\u00e1z\u00e1r, V., Pal Singh, G., Spohn, R., Nagy, I., Horv\u00e1th, B., Hrtyan, M., Busa-Fekete, R., Bogos, B., M\u00e9hi, O., and Cs\u00f6rg\u0151, B. (2013). Bacterial evolution of antibiotic hypersensitivity. Mol. Syst. Biol., 9.","DOI":"10.1038\/msb.2013.57"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"204ra132","DOI":"10.1126\/scitranslmed.3006609","article-title":"Use of collateral sensitivity networks to design drug cycling protocols that avoid resistance development","volume":"5","author":"Imamovic","year":"2013","journal-title":"Sci. Transl. Med."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"3673","DOI":"10.1038\/s41467-018-06143-y","article-title":"Conserved collateral antibiotic susceptibility networks in diverse clinical strains of Escherichia coli","volume":"9","author":"Podnecky","year":"2018","journal-title":"Nat. Commun."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1038\/s41467-018-08098-6","article-title":"Antibiotic collateral sensitivity is contingent on the repeatability of evolution","volume":"10","author":"Nichol","year":"2019","journal-title":"Nat. Commun."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"e00441-22","DOI":"10.1128\/mbio.00441-22","article-title":"Evolutionary instability of collateral susceptibility networks in ciprofloxacin-resistant clinical Escherichia coli strains","volume":"13","author":"Harms","year":"2022","journal-title":"MBio"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1976","DOI":"10.1038\/s41467-023-37624-4","article-title":"Collateral sensitivity profiling in drug-resistant Escherichia coli identifies natural products suppressing cephalosporin resistance","volume":"14","author":"Liu","year":"2023","journal-title":"Nat. Commun."},{"key":"ref_60","first-page":"141","article-title":"Epidemiological Features, Biochemical Indices, Antibiogram Susceptibility Profile and Biofilm Factor Genes of Klebsiella pneumoniae Isolated from Bovine Clinical Mastitis Cases","volume":"44","author":"Shehata","year":"2024","journal-title":"Pak. Vet. J."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1021\/bi5000564","article-title":"Mechanism of quinolone action and resistance","volume":"53","author":"Aldred","year":"2014","journal-title":"Biochemistry"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"eesp00102022","DOI":"10.1128\/ecosalplus.esp-0010-2022","article-title":"The mar, sox, and rob systems","volume":"11","author":"Chubiz","year":"2023","journal-title":"EcoSal Plus"},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Agnello, M., Finkel, S.E., and Wong-Beringer, A. (2016). Fitness cost of fluoroquinolone resistance in clinical isolates of Pseudomonas aeruginosa differs by type III secretion genotype. Front. Microbiol., 7.","DOI":"10.3389\/fmicb.2016.01591"},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Bhatnagar, K., and Wong, A. (2019). The mutational landscape of quinolone resistance in Escherichia coli. PLoS ONE, 14.","DOI":"10.1371\/journal.pone.0224650"},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Vanacker, M., Lenuzza, N., and Rasigade, J.-P. (2023). The fitness cost of horizontally transferred and mutational antimicrobial resistance in Escherichia coli. Front. Microbiol., 14.","DOI":"10.3389\/fmicb.2023.1186920"},{"key":"ref_66","unstructured":"FDA (2025, September 23). FDA Drug Safety Communication: FDA Updates Warnings for Oral and Injectable Fluoroquinolone Antibiotics Due to Disabling Side Effects, Available online: https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-drug-safety-communication-fda-updates-warnings-oral-and-injectable-fluoroquinolone-antibiotics."},{"key":"ref_67","unstructured":"WHO (2025, September 26). WHO Updates List of Drug-Resistant Bacteria Most Threatening to Human Health. Available online: https:\/\/www.who.int\/news\/item\/17-05-2024-who-updates-list-of-drug-resistant-bacteria-most-threatening-to-human-health."},{"key":"ref_68","doi-asserted-by":"crossref","unstructured":"Schuster, S., Bohnert, J.A., Vavra, M., Rossen, J.W., and Kern, W.V. (2019). Proof of an outer membrane target of the efflux inhibitor Phe-Arg-\u03b2-naphthylamide from random mutagenesis. Molecules, 24.","DOI":"10.3390\/molecules24030470"}],"container-title":["Diagnostics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-4418\/15\/22\/2831\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T05:15:22Z","timestamp":1762924522000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-4418\/15\/22\/2831"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,7]]},"references-count":68,"journal-issue":{"issue":"22","published-online":{"date-parts":[[2025,11]]}},"alternative-id":["diagnostics15222831"],"URL":"https:\/\/doi.org\/10.3390\/diagnostics15222831","relation":{},"ISSN":["2075-4418"],"issn-type":[{"value":"2075-4418","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,7]]}}}